Altered IκBα expression promotes NF-κB activation in monocytes from primary Sjo gren's syndrome patients

Pathology

Volumn 44, Issue 6, 2012, Pages 557-561

  Lisi, Sabrina ^a   Sisto, Margherita ^a   Lofrumento, Dario Domenico ^c   D'Amore, Massimo ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF SALENTO   (Italy)

Author keywords

Autoimmunity; Inflammation; I B ; NF B; Sjo gren's syndrome

Indexed keywords

EID: 84866933952     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283580388     Document Type: Article

References (28)

1. Fox PC. Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci 2007; 1098: 15-21.
2. Azuma M, Motegi K, Aota K, Hayashi Y, Sato M. Role of cytokines in the destruction of acinar structure in Sjogren's syndrome salivary glands. Lab Invest 1997; 77: 269-80.
3. Lisi S, Sisto M, Lofrumento DD, et al. Pro-inflammatory role of Anti-Ro/ SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis. J Autoimmun 2010; 35: 160-70.
4. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
5. Baeuerle PA. Pro-inflammatory signaling: last pieces in the NFkappa B puzzle? Curr Biol 1998; 8: R19-22.
6. Tak PP, Firestein GS. NF-kappa B: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
7. Dale E, Davis M, Faustman DL. A role for transcription factor NF-kappa B in autoimmunity: possible interactions of genes, sex, and the immune response. Adv Physiol Educ 2006; 30: 152-8.
8. Sisto M, Lisi S, Lofrumento DD, et al. A failure of TNFAIP3 negative regulation maintains sustained NF-kB activation in Sjogren's syndrome. Histochem Cell Biol 2011; 135: 615-25.
9. Li Q, Verma IM. NF-kappa B regulation in the immune system. Nat Rev Immunol 2002; 2: 725-34.
10. Baldwin AS. The NF-kB and IkB proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649-81.
11. Foxwell B, Browne K, Bondeson J, et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci USA 1998; 95: 8211-5.
12. Tas SW, Vervoordeldonk MJ, Hajji N, et al. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 2006; 8: R86.
13. Schneider C, Strayhorn WD, Brantley DM, et al. Upregulation of 8-lipoxygenase in the dermatitis of IkappaB-alpha-deficient mice. J Invest Dermatol 2004; 122: 691-8.
14. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. European Study Group on Classification Criteria for Sjogren's Syndrome. Ann Rheum Dis 2002; 61: 554-8.
15. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974; 37: 217-29.
16. Sisto M, Lisi S, Castellana D, et al. Autoantibodies from Sjogren's syndrome induce activation of both the intrinsic and extrinsic apoptotic pathways in human salivary gland cell line A-253. J Autoimmun 2006; 27: 38-49.
17. Wildenberg ME, Welzen-Coppens JM, van Helden-Meeuwsen CG, et al. Increased frequency of CD16 monocytes and the presence of activated dendritic cells in salivary glands in primary Sjogren syndrome. Ann Rheum Dis 2009; 68: 420-6.
18. Willeke P, Gaubitz M, Schotte H, et al. Clinical and immunological characteristics of patients with Sjogren's syndrome in relation to alphafodrin antibodies. Rheumatology (Oxford) 2007; 46: 479-83.
19. Kimura-Shimmyo A, Kashiwamura SI, Ueda H, et al. Cytokine-induced injury of the lacrimal and salivary glands. J Immunother 2002; 25: S42-51.
20. Yoshimoto K, Tanaka M, Kojima M, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren's syndrome. Arthritis Res Ther 2011; 13: R170.
21. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651.
22. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004; 82: 434-48.
23. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998; 95: 749-58.
24. Beg AA, Finco TS, Nantermet PV, Baldwin AS. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IkB: a mechanism for NF-kB activation. Mol Cell Biol 1993; 13: 3301-10.
25. Lawrence T, Fong C. The resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int J Biochem Cell Biol 2010; 42: 519-23.
26. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NFkappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42.
27. Lisi S, Sisto M, Lofrumento DD, D'Amore M. Sjogren's syndrome autoantibodies provoke changes in gene expression profiles of inflammatory cytokines triggering a pathway involving TACE/NF-kB. Lab Invest 2012; 92: 615-24.
28. Klement JF, Rice NR, Car BD, et al. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol 1996; 16: 2341-9.